Covered recipient · General Payments record
DAVID N IVANICK
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2019–2024
$3,213.13
- Reported across 25 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $502.75 | 14 |
| Education | $100.00 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ARGENX US, INC. | $353.34 | 8 |
| Alexion Pharmaceuticals, Inc. | $100.00 | 2 |
| UCB, Inc. | $56.64 | 2 |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $47.76 | 2 |
| CSL Behring | $26.15 | 1 |
| Janssen Scientific Affairs, LLC | $18.86 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $50.00 | 04/11/2024 | Education | Undisputed | 01/23/2026 | 1093930372 | CMS |
| Alexion Pharmaceuticals, Inc. | $50.00 | 07/18/2024 | Education | Undisputed | 01/23/2026 | 1093935338 | CMS |
| ARGENX US, INC. | $31.30 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142103859 | CMS |
| ARGENX US, INC. | $95.01 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142106043 | CMS |
| ARGENX US, INC. | $37.31 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142106205 | CMS |
| ARGENX US, INC. | $6.25 | 05/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142106203 | CMS |
| ARGENX US, INC. | $31.55 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142111891 | CMS |
| ARGENX US, INC. | $26.67 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142110329 | CMS |
| ARGENX US, INC. | $29.74 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142123035 | CMS |
| ARGENX US, INC. | $95.51 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142118524 | CMS |
| CSL Behring | $26.15 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134657407 | CMS |
| Janssen Scientific Affairs, LLC | $18.86 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078861719 | CMS |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $21.33 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144506630 | CMS |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $26.43 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144510758 | CMS |
| UCB, Inc. | $43.50 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143333605 | CMS |
| UCB, Inc. | $13.14 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143333609 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.